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PolySUMO chainsProtein modiﬁcation with the small ubiquitin-like modiﬁer (SUMO) is a reversible process regulatingmany cen-
tral biological pathways. The reversibility of SUMOylation is ensured by SUMO proteases many of which belong
to the sentrin/SUMO-speciﬁc protease (SENP) family. In recent years, many advances have beenmade in allocat-
ing SENPs to speciﬁc biological pathways. However, due to difﬁculties in obtaining recombinant full-length active
SENPs for thorough enzymatic characterization, our knowledgeon these proteases is still limited. In thiswork,we
used in vitro synthesized full-length human SENPs to perform a side-by-side comparison of their activities and
substrate speciﬁcities. ProSUMO1/2/3, RanGAP1–SUMO1/2/3 and polySUMO2/3 chains were used as substrates
in these analyses. We found that SENP1 is by far the most versatile and active SENP whereas SENP3 stands out
as the least active of these enzymes. Finally, a comparison between the activities of full-length SENPs and their
catalytic domains suggests that in some cases their non-catalytic regions inﬂuence their activity.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The post-translational modiﬁcation of proteins with the small
ubiquitin-like modiﬁer (SUMO) plays a central role in cell homeostasis
by regulating a large number of key biological processes such as DNA
repair, transcription and cell cycle progression [1,2]. Mammals express
three SUMO paralogues—SUMO1, and the nearly identical and
functionally indistinguishable SUMO2 and SUMO3 [3–7]. The three
SUMO paralogues are conjugated to target-proteins through an enzy-
matic cascade comprising one SUMO-activating enzyme [8], one
SUMO-conjugating enzyme [9] and, in some cases, also a SUMO ligase
[10]. This machinery activates the C-terminal glycine carboxyl
group of SUMO in an ATP-dependent process and conjugates it to the
ε-amino group of a lysine residue in target proteins [2,11]. As
with ubiquitination, proteins can be modiﬁed with a single SUMO
molecule (monoSUMOylation) or with a chain of SUMO molecules
(polySUMOylation) [2]. Polymeric chains are built by attaching a new
SUMO moiety to lysine 11 of the previous SUMO molecule [6,12]. Dueentrin/SUMO-speciﬁc protease;
e modiﬁer; VME, vinyl methyl
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, mabp@ibmc.up.pt (M.P. Pinto).to the fact that SUMO1 lacks this lysine residue, only SUMO2 and
SUMO3 are involved in polySUMO chain elongation [12].
Protein modiﬁcation by SUMO is a highly dynamic and transient
process, readily reverted by the action of SUMO proteases, hydrolases
that remove SUMO or SUMO chains from SUMOylated proteins [2,13].
Most SUMO proteases belong to the so-called sentrin/SUMO-speciﬁc
protease (SENP) family of cysteine proteases. In mammals there
are six SENPs. They are often classiﬁed into three groups according to
sequence relationships and predominant subcellular localization
[2,13–15]. The ﬁrst group comprises SENP1 and SENP2, both localizing
mainly to the nuclear periphery [16–18]. The second group consists
of SENP3 and SENP5 [19,20], which localize mostly to the nucleolus.
The third group comprises SENP6 and SENP7 [21,22], two enzymes
mainly found in the nucleoplasm. All SENPs are structurally orga-
nized into a C-terminal catalytic domain and a non-conserved N-
terminal region which comprises around two-thirds of their poly-
peptide chains [2,13].
In addition to SENPs, three other SUMO proteases have been
described recently in mammals: the deSUMOylating isopeptidases
DeSI-1 and DeSI-2 [23], and the ubiquitin-speciﬁc protease-like 1
(USPL1) [24]. These enzymes are also cysteine proteases but they are
very distantly related to the SENP family. Also, they probably act on a
very restricted set of substrates because knockdown of any of these
enzymes in cell lines does not lead to detectable alterations in the
bulk of SUMO conjugated products [23,24]. The minor roles of each of
these enzymes in the global cell SUMOylation status [23,24] contrast
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lacking any of the SENP family members [19,22,25–29].
Besides a major role in controlling the SUMOylation status of many
proteins, SENPs are also involved in the de novo synthesis of SUMO
[19,20,30–32]. Indeed, the three SUMOparalogues are expressed as pre-
cursor proteins (proSUMO1/2/3) thatmust be processed to yield the ac-
tive/conjugatable proteins. Processing involves the removal of small
peptide extensions that are present at the C termini of proSUMOs [2].
Although the involvement of SENPs in several biological processes is
nowwell established, their substrates speciﬁcities and activities are still
ill-characterized. A major problem in addressing this issue stems from
the fact that, thus far, it has not been possible to obtain recombinant
active full-length SENPs for thorough enzymatic characterization.
Thus, most studies on SENP activity and speciﬁcity have used recombi-
nant truncated proteins comprising only their catalytic domains in en-
zymatic assays with natural or artiﬁcial substrates [19,22,30,33–37]. In
the case of SENP3, even this type of data are lacking due to problems
in obtaining a stable and active catalytic domain [30]. Other studies
have looked at the reactivity of endogenous or epitope-tagged SENPs
in cell extracts towards activity-based irreversible inhibitors such as
SUMO1 and SUMO2 vinyl sulfones (VS) [21,38,39]. One of these studies
revealed that (full-length) SENP1 reacts equallywell with both SUMO1-
VS and SUMO2-VS whereas all the other SENPs show a preference for
SUMO2-VS [38]. Interestingly, it was also shown that the recombinant
catalytic domains of SENPs no longer display a SUMO paralogue prefer-
ence when tested with the activity-based inhibitors. Seemingly, the N-
terminal non-catalytic domains of SENPs somehow modulate SENP ac-
tivity/substrate speciﬁcity [2,13], thus raising some doubts on whether
or not the enzymatic data reported for SENP catalytic domains can be
extrapolated to the full-length enzymes. Clearly, additional studies
using intact enzymes and their natural substrates are needed to better
understand the properties of these proteases.
2. Materials and methods
2.1. Plasmids and proteins
The cDNAs encoding human full-length SENP1/2/5/6 were opti-
mized for Escherichia coli expression (GenScript) and cloned into the
NdeI/XhoI sites of pET28a. The plasmids encoding human full-length
SENP3 and SENP7 in pET28a were described before [40]. Flag-tagged
pcDNA5/FRT/TO-derived constructs of wild type (WT) SENP7, of a
mutant lacking seven putative SUMO-interacting motifs (SIMs) in the
N-terminal region (SM) and of the catalytic inactive C992A mutant
(CA) were kindly provided by Dr. Joanna R. Morris (University of
Birmingham, UK) [41]. These plasmids were digested with KpnI/XhoI
and the DNA inserts were cloned into pcDNA3.1, which contains a T7
promoter, for in vitro synthesis. The pET28a-derived plasmids coding
for the catalytic domains of human SENP1/2/5–7 were a kind gift from
Dr. Guy Salvesen [30]. The cDNA encoding SENP3 catalytic domain,
SENP3(307–574), was ampliﬁed by PCR using as template SENP3-
pET28a and cloned into the NdeI/XhoI sites of pET28a. A plasmid
encoding untagged human full-length RanGAP1 (RanGAP1-pET23a)
was obtained from Addgene (plasmid #13387) [42]. The plasmid ΔC1-
PEX5-pET28a was described elsewhere [43].
Recombinant full-length His6-SENP1 was expressed in Rosetta
2(DE3) E. coli cells with 0.5 mM IPTG for 3 h at 30 °C. After cell lysis in
buffer A (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 10% (w/v) glycerol)
supplemented with 1:500 (v/v) protease inhibitors cocktail (Sigma),
0.25 mg/ml PMSF and 1 mM DTT, inclusion bodies were washed twice
with the same buffer in the presence of 1% (w/v) Triton X-100. The
plasmid pTYB-SUMO2 [40] was used to produce HA-tagged SUMO2
vinyl methyl ester (HA-SUMO2-VME) as previously described [44],
excluding the ion-exchange puriﬁcation step. Plasmids encoding
SUMO2, SUMO3, Ubc9 and SAE1/SAE2 (SUMOE1)were kindly provided
by Dr. Frauke Melchior [45,46] and used to prepare the respectiverecombinant proteins as described [47]. Recombinant untagged
SUMO1, proSUMO1-3, polySUMO2 and polySUMO3 were purchased
from Boston Biochem or Enzo Life Sciences. Radiolabeled proteins
were synthesized in vitro using pET- or pcDNA3.1-based plasmids
with the TNT® T7 Quick Coupled Transcription/Translation System
(Promega), in the presence of EasyTag™ L-[35S]-Methionine (Perkin
Elmer, speciﬁc activity N1000 Ci (37.0 TBq)/mmol), according to the
manufacturer's instructions. Translation reactions were stopped by
incubation with 1 mM cycloheximide (Sigma) for 10 min at 30 °C.
2.2. Covalent labeling of SENPs with HA-SUMO-VME
In vitro synthesized 35S-labeled full-length SENPs (0.5–1 μl), proteins
comprising their catalytic domains alone (0.02–0.1 μl) or HeLa cell
total homogenates (200 μg of total proteins, prepared as described
[40]) were incubated with 0.2–0.4 μM HA-SUMO2-VME for 15 min at
25 °C in 20 μl (ﬁnal volume) of buffer A supplemented with 2 mM
EDTA-NaOH, pH 8.0, 0.15 μg/μl BSA and 1 mM DTT. Reactions were
stopped with Laemmli sample buffer and analyzed by SDS-PAGE/
autoradiography.
2.3. RanGAP1 monoSUMOylation assay
Full-length RanGAP1was synthesized in vitro for 45min and treated
with 1mMcycloheximide for 10min at 30 °C to prevent further protein
synthesis. Samples were then diluted twofold with buffer A supple-
mented with 1 mM DTT, 2 mMMgCl2 and 2 mM ATP (ﬁnal concentra-
tions) and incubated for 40 min at 37 °C in the presence of 50 nM E1,
100 nM Ubc9 and 1 μM of either SUMO1 or SUMO2 or SUMO3.
SUMOylation reactions were terminated by depleting ATP with 5 U/ml
(ﬁnal concentration) of apyrase (grade VII, Sigma) for 10 min at 30 °C.
2.4. Densitometric analyses
In vitro synthesized full-length SENP1, HeLa cell total proteins and
different amounts of recombinant full-length SENP1 were analyzed by
SDS-PAGE/western-blot using an anti-SENP1 antibody. The approxi-
mate levels of 35S-labeled SENP1 produced in the rabbit reticulocyte
lysate (RRL) and of the endogenous enzyme in HeLa cells were deter-
mined by direct comparison with the recombinant protein, as assessed
by densitometric analyses of western-blots using ImageJ software
(Rasband, W.S., ImageJ, U. S. National Institutes of Health, Bethesda,
Maryland, USA, http://imagej.nih.gov/ij/, 1997–2014). To estimate the
relative stoichiometries of the in vitro synthesized SENPs to be used in
the activity assays (Section 2.5.), aliquots of the RRLs containing the
35S-labeled proteins were subjected to SDS-PAGE/autoradiography
followed by densitometry analyses, taking into account the methionine
content of each enzyme. Full-length SENP1/2/3/5/6/7 contain 14, 15, 15,
17, 14 and 14 methionines, respectively, whereas the corresponding
catalytic domains contain 11, 9, 10, 7, 10 and 6 methionine residues,
respectively.
2.5. SENP activity assays
The activity of in vitro synthesized SENPs was assessed by HA-
SUMO2-VME labeling. Approximate equimolar amounts of each
SENP (see Section 2.4.) were then used in the activity assays unless
otherwise indicated. The total volume of RRL used in each reaction
was made equal by addition of a mock-translated and
cycloheximide-treated RRL. A control RRL containing an in vitro syn-
thesized unrelated protein, 35S-labeled ΔC1-PEX5 [43], was also
included in many assays as speciﬁed. The activity assays were per-
formed at 25 °C in the presence of 0.6–2 μl of monoSUMOylated
RanGAP1 or 250 ng of polySUMO chains in 10 μl of buffer A supple-
mented with 2 mM EDTA-NaOH, pH 8.0, 0.15 μg/μl BSA and 2 mM
DTT. For the activity assays with SUMO precursors, 200–500 ng of
Fig. 1. In vitro synthesized full-length SENPs are active. A. 35S-labeled full-length SENPs
were synthesized in vitro and incubated at 25 °C in the absence (−) or presence (+) of
HA-SUMO2-VME (VME). Reactions were analyzed by SDS-PAGE/autoradiography. B.
SENP1 levels in HeLa cells and in the rabbit reticulocyte lysate. Increasing amounts of bac-
terially expressed recombinant full-length SENP1 (rSENP1, lanes 1–3; 1.5, 3 and 6 ng, re-
spectively), in vitro synthesized SENP1 (35S-SENP1, lanes 5–6; 0.5 and 1 μl, respectively)
andHeLa cell total proteins (HeLa, lanes 7–8; 100 and 200 μg, respectively)were subjected
to SDS-PAGE/western-blot and probed with an anti-SENP1 antibody. The RRL synthesizes
3.2 ± 0.3 ng/μl of 35S-labeled SENP1 and HeLa cells contain 2.1 ± 0.6 ng of endogenous
SENP1 per 100 μg of total proteins, as determined by densitometric analysis (see
Section 2.4.). An RRL containing an in vitro synthesized control protein (see Section 2.5.)
was also analyzed (Ctrl RRL, lane 4; 1 μl), as well as an aliquot of HeLa cell total proteins
(200 μg) previously subjected to HA-SUMO2-VME labeling (lane 9). Unmodiﬁed (SP1)
and modiﬁed (SP1′) SENP1 species are indicated. Asterisk, non-speciﬁc band detected
by the anti-SENP1 antibody in HeLa cells. Molecular masses of protein standards in kDa
are shown to the left of the panels.
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plus SENP-containing RRL) and incubated at 25 °C. The approximate
concentrations of SENP1 in these assays were 6–7 nM, 3–5 nM and
1–2 nM for proSUMOs, RanGAP1–SUMOs and polySUMO chains,
respectively, as judged from the determinations with the anti-SENP1
antibody (Section 2.4.). In the activity assays containing the catalytic
domains and SENP7 mutants, the incubation times and/or amounts of
enzyme used were adjusted to obtain partial substrate hydrolysis.
SENP-containing RRLs used in the assays with monoSUMOylated
RanGAP1were pretreatedwith apyrase (see Section 2.3.) to prevent reac-
tivation of the exogenously added SUMO-conjugation machinery. Reac-
tions from the activity assays with RanGAP1–SUMO were stopped with
Laemmli sample buffer, separated in 8 or 12% SDS-PAGE and blotted
onto a nitrocellulose membrane, followed by autoradiography to detect
the radiolabeled proteins (SENPs, RanGAP1 andΔC1-PEX5). In the activity
assayswith SUMOprecursors and polySUMO chains, two aliquots of each
samplewere withdrawn after stopping the reactions. One aliquot was re-
solved in 16% SDS-PAGE and analyzed by western-blot with anti-SUMO1
or anti-SUMO2/3 antibodies to detect proSUMOs, polySUMO chains and
their hydrolysis products. The second aliquot was analyzed by 8% SDS-
PAGE/autoradiography to detect the radiolabeled SENPs. The stoichio-
metric ratios of SENPs were then reassessed by densitometry analyses
(see Section 2.4.) and are presented in the ﬁgures. The contribution to
SENP2 and SENP3 intensity signals from the band of the RanGAP1 doublet
that co-migrates with those enzymes in some gels was estimated and
subtracted by analyzing the intensity of the other RanGAP1 band and
the stoichiometry of the RanGAP1 doublet in other lanes. All assays
were performed at least three times; representative experiments are
shown.
2.6. Antibodies
Mouse monoclonal anti-SUMO1 (21C7) [5] and anti-SUMO2/3
(8A2) [48] antibodieswere developed byMichael J.Matunis and obtain-
ed from the Developmental Studies Hybridoma Bank, created by the
NICHD of theNIH andmaintained at theUniversity of Iowa, Department
of Biology, Iowa City, IA 52242, USA. Rabbit polyclonal anti-SENP1 anti-
body (A302-927A-1) was purchased from Bethyl Laboratories, Inc.
These antibodies were detected on western-blots using alkaline
phosphatase-conjugated anti-mouse or anti-rabbit IgGs (Sigma).
3. Results
As shown previously [40], full-length human SENPs synthesized in a
RRL-based in vitro transcription/translation system are quite active as
assessed by their reactivity toward the activity-based irreversible inhib-
itor SUMO2 vinylmethyl ester (SUMO2-VME; see Fig. 1A). Furthermore,
the amounts of protein produced by the RRL, although orders of magni-
tude lower than those typically obtained using in vivo expression
systems, are considerable. Indeed, as shown in Fig. 1B, 1 μl of RRL pro-
duces approximately 3 ng of SENP1, an amount similar to that present
in 100–200 μg of total proteins from HeLa cells. These two ﬁndings led
us to conclude that in vitro synthesized SENPs might be used in enzy-
matic assays aiming at better understanding their substrate speciﬁcities
and relative activities. The strategy developed for this purpose turned
out to be very simple because the endogenous SUMO protease activity
of the RRL is relatively low. Indeed, with very few exceptions (e.g., see
Fig. 2C, lower right panel), the activities detected in RRLs containing a
negative control protein were always much lower than those detected
in RRLs containing SENPs. This obviated the need to purify SENPs from
the RRL before proceeding with the activity assays. Thus, aliquots of
the in vitro translation reactions were simply mixed with a test
substrate in an appropriate buffer and incubated (see Section 2.5. for
details). Because one of our aims was also to gather qualitative
information on the relative activities of the different SENPs, their rela-
tive stoichiometries in each of the experiments presented below wereestimated by densitometric analyses of autoradiographs (see legends
to ﬁgures and Section 2.4. for details).
Fig. 2A shows the results obtained with SUMO1/2/3 precursors.
Fromall human SENPs, only SENP1 and SENP2 showdetectable process-
ing activity, with the former being more active on proSUMO1 and the
latter preferring proSUMO2 and proSUMO3. We next assessed
the isopeptidase activity of the different SENPs using as a substrate
monoSUMOylated RanGAP1, a nuclear pore protein and a canonical tar-
get of SUMOylation [5,49]. Radiolabeled RanGAP1 modiﬁed with
SUMO1 or SUMO2 was produced in vitro (Fig. 2B; see Section 2.3.) and
incubated with radiolabeled SENPs. Note that RanGAP1 migrates in
SDS-gels as a double band, a result of phosphorylation events occurring
in the RRL [50]. As shown in Fig. 2C (upper left panel), SENP1 is by
far the most active isopeptidase achieving complete deconjugation
of RanGAP1–SUMO1 in 5 min or less. SENP2 also hydrolyzes the
RanGAP1–SUMO1 conjugate but this activity was detectable only after
a 1-h incubation (upper right panel). Different results were obtained
with RanGAP1–SUMO2 (Fig. 2C, lower panels). In this case, SENP1 is
again the most active isopeptidase, but SENP2 now shares with SENP5
the second largest activity (left panel). No hydrolysis of RanGAP1–
SUMO2 was detected in the 5 min incubation assay when testing
SENP3, SENP6 and SENP7 (Fig. 2C, left panel). A longer incubation did
reveal some hydrolysis of this substrate in the SENP3/6/7-containing
RRLs. However, the amounts of RanGAP1–SUMO2 hydrolyzed in these
samples are similar to or, at best, only slightly larger than the one ob-
tained with a negative control RRL (right panel, compare lane C with
lanes 3, 6 and 7). Substituting RanGAP1–SUMO3 for RanGAP1–SUMO2
in these assays yielded the same results (data not shown).
Fig. 2.Activity proﬁling of SENPswith SUMO precursors andmonoSUMOylated substrates. A. Similar amounts of 35S-labeled full-length SENP1-3/5–7were incubated for 2 h at 25 °Cwith
proSUMO1 (pS1), proSUMO2 (pS2) or proSUMO3 (pS3). At the end of the incubation, two aliquots of each sample werewithdrawn. One aliquot was run on a 16% SDS-PAGE followed by
western-blot with anti-SUMO1 or anti-SUMO2/3 antibodies to detect both the SUMO precursors and their hydrolysis products SUMO1 (S1), SUMO2 (S2) and SUMO3 (S3). The second
aliquot was subjected to 8% SDS-PAGE/autoradiography to detect the radiolabeled SENPs (1–7, upper panel). Their stoichiometric ratios as determined by densitometry analysis are
also shown (see Section 2.4. for details). B. In vitro synthesized full-length RanGAP1 (−) was subjected to SUMOylation with either SUMO1 (S1) or SUMO2 (S2). Unconjugated (RG)
and SUMOylated RanGAP1 (RG–S) are indicated. C. 35S-labeled full-length SENPs (1–7) were incubated at 25 °C for 5 min (left panels) or 1 h (right panels) in the presence of
RanGAP1–SUMO1 (RG–S1, upper panels) or RanGAP1–SUMO2 (RG–S2, lower panels). Samples were analyzed by SDS-PAGE/autoradiography to detect both RanGAP1 (RG) and SENPs
(asterisks). Molar ratios of SENPs were determined as in B. Lanes C contain an irrelevant in vitro synthesized protein (asterisk) to control the activity of endogenous SENPs from the
RRL. Lane I, SENP substrate used in each reaction.
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As shown in Fig. 3, all SENPs display at least some activity with this
substrate. Interestingly, SENP1 and SENP2 seem to be at least as active
(if notmore) as SENP6 and SENP7, the two enzymes typically associated
with polySUMO disassembly. Also, the activity of SENP6 on polySUMO2
chains seems larger than that of SENP7. However, due to the fact that
in vitro synthesis of both SENP6 and SENP7 also results in the synthesis
of signiﬁcant amounts of truncated fragments (some of which may be
catalytically active) this observation should be taken with caution.
SENP3 and SENP5 are the least efﬁcient SENPs in polySUMO2 chaindisassembly (lower panel, lanes 3 and 5, respectively). The same results
were obtained with polySUMO3 chains (data not shown).
As stated above (Section 1.) there are some data suggesting that the
non-catalytic N-terminal domains of SENPs may somehow modulate
the activities of these enzymes. The availability of active full-length
human SENPs prompted us to compare their activities with those of
the corresponding catalytic domains. The catalytic domains of SENP1/
2/5/6/7 used in these experiments were those deﬁned before by other
authors [30] (see Section 2.1.). For SENP3, the previously deﬁned
catalytic domain (residues 353–574; [30]) turned out to be inactive, as
Fig. 3. PolySUMO2 chain disassembly activity of SENPs. In vitro synthesized full-length
SENPs (1–7, upper panel) were incubated for 2 h at 25 °C with polySUMO2 chains (1×,
middle panel). Similar reactions containing ﬁvefold more SENPs (5×) were also prepared
(lower panel). After stopping the reactions, two aliquots were withdrawn. One aliquot
was analyzed in 16% SDS-PAGE followed bywestern-blot with an anti-SUMO2/3 antibody.
SUMO2 (S2) and chains containing two to ﬁve SUMO moieties (S22–S25) are indicated.
Note that monomeric SUMO2 runs in these gels together with the very abundant hemo-
globin protein from the reticulocyte lysate, partially hampering its detection in western-
blots. The other aliquot was analyzed by 8% SDS-PAGE/autoradiography to detect
radiolabeled SENPs (upper panel). Their stoichiometric ratios are also indicated (see leg-
end to Fig. 2). An unrelated in vitro synthesized protein (C) was included in these assays
to control for background activity. Lane I, polySUMO2 chains used in each reaction.
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used instead a protein comprising residues 307–574 of SENP3,
the shortest SENP3 protein tested that reacted quantitatively with
SUMO2-VME (see Fig. 4A). Note that the experimental conditions
used in these assays for each SENP/catalytic domain pair were not the
same and differ from those used in Fig. 3. Speciﬁcally, the incubation
times and/or the amounts of enzyme in the assays were changed in
order to avoid less informative situations of complete substrate
hydrolysis.
The results of this comparison using polySUMO2 chains as substrate
are shown in Fig. 4B. No obvious differences between the activities of
full-length SENP2 and SENP3 and their catalytic domainswere observed
in these experiments. For SENP1we did observe a larger activitywith its
catalytic domain than with the full-length enzyme. This difference,
however, is modest, as increasing the amount of full-length SENP1 in
the assay by a factor of ~2 yields approximately the activity observed
for its catalytic domain. Furthermore, no difference in the activities of
full-length SENP1 and its catalytic domain was detected when using
RanGAP1–SUMO2 as substrate (Fig. 4C). In contrast, marked differencesbetween the activities of full-length enzymes and their catalytic do-
mains were observed for SENP5, SENP6 and SENP7 with polySUMO2
chains, but in these cases in the opposite direction (Fig. 4B). That is,
their catalytic domains are much less active than the corresponding
full-length enzymes. Again, for the reasons stated above these differ-
ences should be taken with caution in the cases of SENP6 and SENP7
(see also below). The lower activity of SENP5 catalytic domain com-
pared to the full-length enzyme is also easily detectable when using
RanGAP1–SUMO2 as a substrate (Fig. 4C).
The non-catalytic N-terminal domains of several SENPs contain one
or more SIMs [51]. These SIMs might act as substrate recruiting
platforms and thus they could explain why full-length SENP5/6/7
are more active than the corresponding catalytic domains in the
polySUMO2 hydrolysis assays presented above. To test this possibility,
we used a SENP7 mutant protein that lacks seven of these SIMs and
which was recently shown to be rather inefﬁcient in homologous
recombination DNA repair, a SUMO-dependent process that requires
catalytically active SENP7 [41]. Unexpectedly, as shown in Fig. 5B,
the mutant SENP7 protein is as efﬁcient as SENP7 in disassembling
polySUMO2 chains. Apparently, these SENP7 SIMs are not relevant for
the enzyme activity, at least in these in vitro assays.4. Discussion
From the qualitative assessment of SENP activities presented in this
work (see Table 1) it is clear that SENP1 is one of the most active SENPs
and the only one for which we could detect activity with all the sub-
strates tested. Two observations areworth noting. The ﬁrst is the almost
exclusive capacity of SENP1 to cleave the two SUMO1-containing sub-
strates used here. Indeed, under our experimental conditions, no other
SENP cleaved proSUMO1 and only SENP2 displayed some activity on
RanGAP1–SUMO1. This ﬁnding should not be taken as evidence to con-
clude that only SENP1 is capable of cleaving proSUMO1—as shown
before, recombinant full-length SENP2 as well as the catalytic domains
of SENP2 and SENP5 is also able to cleave proSUMO1 in vitro,
when used at concentrations several fold larger than the ones used
here [19,30,32,33,35]. What is apparent from our results is that SENP1
is by far the most efﬁcient SENP acting on SUMO1-containing
substrates, a ﬁnding re-enforcing the idea that this protease plays an es-
sential role in all processes involving SUMO1 [29,52]. The second inter-
esting result regards the activity of full-length SENP1 on polySUMO2/3
chain disassembly. Previous studies have shown that the catalytic do-
main of SENP1 is more active on polySUMO2 chain hydrolysis than
those of SENP6 and SENP7 [22,53], but whether or not these ﬁndings
were valid for the full-length enzymes remained unknown. Here, we
show that full-length SENP1 is one of the most active enzymes, if not
the most efﬁcient, towards polySUMO2/3 chains. Furthermore, our
data suggest that this is probably an intrinsic property of its catalytic do-
main (see Fig. 4B). Thus, the idea that disassembly of polySUMO2/3
chains is a function performed mainly by SENP6 and SENP7 [2,15,54],
seems unlikely.
SENP2, the enzyme more closely related to SENP1, also presents a
large catalytic activity and broad substrate speciﬁcity but, in contrast
to SENP1, displays a strong preference for SUMO2/3-containing sub-
strates. These ﬁndings are consistent with data reported previously for
the recombinant catalytic domain of this protease [30,35], as well as
with the fact that Senp2 knockout mouse embryos present a strong ac-
cumulation of SUMO2/3 conjugates and depletion of free SUMO2/3,
while the levels of free and conjugated SUMO1 remain essentially
normal [27]. Our data also suggest that full-length SENP2, and not
SENP1, is the most active SENP acting on proSUMO2 and proSUMO3, a
result that differs from previous data showing that the catalytic domain
of SENP1 is slightly more active than that of SENP2 in cleaving
proSUMO2/3 [30]. Regardless of this difference, which given the non-
quantitative nature of the assays used here and in that study may in
Fig. 4. Inﬂuence of the N-terminal domains of SENPs on their catalytic activity. A. 35S-labeled versions of the catalytic domains (CD) of SENPswere synthesized in vitro and incubated in the
absence (−) or presence (+) of HA-SUMO2-VME (VME) followed by SDS-PAGE/autoradiography analysis. B. Full-length SENPs (FL) and similar stoichiometric amounts of their catalytic
domains alone (CD) were incubated with polySUMO2 chains for 5 min (SENP1/2) or 1 h (SENP3/5–7) at 25 °C. Some reactions contained a molar excess of full-length enzyme (FL+) or
catalytic domain (CD+). Two aliquotswerewithdrawn from each sample. One aliquotwas analyzed by 16% SDS-PAGE/western-blot with an anti-SUMO2/3 antibody to detect polySUMO2
chains and their hydrolysis products (lower panels). SUMO2 (S2) as well as chains containing two to ﬁve SUMO2 units (S22–S25) are indicated. The other aliquot was subjected to SDS-
PAGE (8 or 12%)/autoradiography to detect the radiolabeled SENPs (upper panels). For each SENP, the stoichiometric ratios between the full-length enzyme and the catalytic domain are
shown (see also legend to Fig. 2). C. In vitro synthesized full-length SENP1/5 and their respective catalytic domains were incubated for 5 min at 25 °C using RanGAP1–SUMO2 (RG–S2) as
substrate and analyzed by SDS-PAGE/autoradiography. SENPmolar ratios are also shown. The radiolabeled enzymes aswells as a control protein (C) are indicated by asterisks. Lane I, SENP
substrate used in each lane.
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most active enzymes acting on proSUMO2/3.
Due to difﬁculties in obtaining stable and active recombinant ver-
sions of SENP3, the catalytic properties of this SENP have remainedpoorly characterized. Indeed, besides somedata showing that SENP3 re-
acts with SUMO2/3-VS but not with SUMO1-VS [38–40] and prefers
SUMO2/3-modiﬁed substrates [20,39,55], very little was known. Here
we show that although the in vitro synthesized full-length SENP3 is
Fig. 5.A SENP7mutant lacking seven putative SIMs is as active as thewild type enzyme on
polySUMO2 chain disassembly. A. Radiolabeledwild type SENP7 (WT), a SIMmutant (SM)
and a catalytic inactive C992Amutant (CA)were synthesized in vitro, incubated at 25 °C in
the absence (−) or presence (+) of HA-SUMO2-VME (VME) and analyzed by SDS-PAGE/
autoradiography. B. The wild type (WT), the SIM mutant (SM) and the catalytic inactive
(CA) full-length versions of SENP7 were used in activity assays with polySUMO2 chains
for 1 h at 25 °C. An aliquot of each reaction was analyzed by 16% SDS-PAGE/western-
blot with an anti-SUMO2/3 antibody (lower panel). SUMO2 (S2) and chains containing
two to ﬁve SUMO moieties (S22–S25) are indicated. A second aliquot was subjected to
8% SDS-PAGE/autoradiography to detect the radiolabeled SENP7 versions used in the as-
says (upper panel). The stoichiometric ratio betweenwild type SENP7 and the SIMmutant
is shown (see also legend to Fig. 2). Lane I, polySUMO2 chains used in each reaction.
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VME, the enzyme displays only a minor isopeptidase activity. This
ﬁnding is intriguing when we consider that knockdown of SENP3 in
human/mouse cells leads to a strong accumulation of SUMO2/3 conju-
gates [25,28], a phenomenon consistent with SENP3 controlling the
global levels of SUMO2/3-ylated conjugates. One possibility to explain
this paradox is to assume that our assay lacks some SENP3-activating
factor. If so, our data might suggest that this activating factor does not
act by a de-repressing mechanism on its non-catalytic N-terminal do-
main because the catalytic domain of SENP3 alone also displays a
minor isopeptidase activity. Another possibility is to assume that
SENP3 acts on a large number of substrates but that all these substrates
have some SENP3-interacting domain which, clearly, does not exist in
the substrates used here. Clearly, further data are necessary to under-
stand the properties of SENP3.Table 1
Summary of the relative activities and substrate speciﬁcities of SENPs.
The relative activities of the six SENPs for a given substrate are qualitatively classiﬁed from
the maximum activity detected (+++) to non-detectable (−). Note that this classiﬁca-
tion cannot beused to compare the activity of a given SENP on different substrates because
different experimental conditions were used for each substrate.
SENP1 SENP2 SENP3 SENP5 SENP6 SENP7
ProS1 +++ − − − − −
ProS2 ++ +++ − − − −
ProS3 ++ +++ − − − −
RanGAP1–S1 +++ + − − − −
RanGAP1–S2/3 +++ ++ −/+ ++ −/+ −/+
PolyS2/3 +++ +++ + + +++ ++
S1/2/3, SUMO1/2/3.SENP5 is as efﬁcient as SENP2 in hydrolyzing RanGAP1–SUMO2/3
but shows no detectable activity with RanGAP1–SUMO1 even after
prolonged incubations, suggesting a very strong paralogue preference
for SUMO2/3. By contrast, it is one of the least active SENPs on
polySUMO2/3 chains. This suggests that SENP5 is probablymore impor-
tant in removing monoSUMO2/3 from SUMOylated substrates than in
disassembling polySUMO2/3 chains. Interestingly, in contrast to the re-
sults on SENP1/2/3, the catalytic domain of SENP5 is considerably less
active than the full-length enzyme. This suggests that the N-terminal
non-catalytic domain of SENP5 modulates its activity. Whether the N-
terminal domain of SENP5 increases its substrate afﬁnity or the catalytic
efﬁciency of the enzyme remains to be determined.
As expected from previous ﬁndings [21,22,30,33], SENP6 and SENP7
display a clear preference for polySUMO2/3 chains with very little or no
activity towards the other tested substrates. However, as stated above,
our results also show that SENP1 and SENP2 are at least as active
as SENP6/7, suggesting that SENP6/7 are not alone in the task of
disassembling polySUMO2/3 chains. As with SENP5, we found that the
catalytic domains of SENP6 and SENP7 seem to be less active than the
corresponding full-length enzymes. Since all these SENPs possess puta-
tive SIMs at their non-catalytic N-terminal domains, we considered the
possibility that their N-terminal domains might somehow contribute
for substrate recruitment. Unexpectedly, we found that a biologically
compromised SENP7mutant lacking seven of these SIMs [41] is as active
as the normal protein in polySUMO2 disassembly. Apparently, these
SIMs are not important for SENP7 polySUMO disassembly activity, at
least in our assays. Naturally, given the difﬁculties in deﬁning SIMs
based solely on primary structure analyses (the SIM is quite a degener-
ate motif [51,56–58]), there may be additional SIMs in the N-terminal
domain of SENP7 playing some role in substrate recruitment. However,
it is also possible that the larger activity of full-length SENP7 in compar-
ison with its catalytic domain is due to a stabilizing effect of its N-
terminal domain over its catalytic domain, leading to an increase in
the catalytic efﬁciency of the enzyme. Clearly, additional data are
necessary to clarify these issues.
In summary, herewe describe a simple in vitro approach to study the
properties of SENPs. The data collected, although of qualitative nature,
provide a global perspective on the relative activities and substrates
speciﬁcities of these biochemically intractable enzymes. Such an ap-
proach will be surely useful in any future work aiming at unraveling
the structural/functional relationships of these proteases.
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